• Home
  • » 
  • Reports
  • » 
  • Fc Protein and Glycoengineered Abs Marke...

Fc Protein and Glycoengineered Abs Market, 2013 - 2023

  • Lowest Price Guaranteed From USD 1,699

  • Published
    September 2013

  • Pages
    174

  • View Count
    6116

  • Buy Now

Example Insights

An updated edition is available at the following link 

View 2nd edition

  1. Oncology dominates the field of engineered antibodies. Many drugs are in Phase II and III clinical trials while one drug, mogamulizumab (KW-0761 / POTELIGEO / AMG761), has already received approval for marketing.
  2. By 2023, the overall market is estimated to be in the range of USD 4.3 billion to USD 6.6 billion. The true picture over the forecast period will be determined by the success or failure of the pipeline drugs. We expect the market to be heavily dominated by glycoengineered antibodies.
  3. The growth in this market will continue to be aided by major developments with respect to the technology platforms, which are being designed by various companies.
  4. Although there are several engineered antibodies under development, the number of target antigens which has been explored to date is limited. Most research to date has focused on CD20, CD19 and HER2 as the target antigens.
  5. The market is likely to face competition from other innovative antibody based therapeutics technologies. Antibody drug conjugate (ADC) is one such approach which is attracting the interest of pharmaceutical companies. Two high profile ADCs, namely Adcetris and Kadcyla, have already reached the market.
  6. In addition to the current development focus, there are other emerging opportunities for engineered antibodies. For instance, they can be used as a potent life cycle management tool for companies with marketed monoclonal antibody drugs. Companies with successful antibody drugs nearing patent expiry can explore development of an engineered antibody using mAb.

Report Description

Engineered antibodies are antibody based therapeutics, which are gaining increasing attention from both large and small pharmaceutical companies. Developed through introduction of modifications in monoclonal antibodies, the aim is to develop antibodies with improved efficacy.

Research done in the last decade to develop engineered antibodies has yielded a rich knowledge base on how to develop and market these next generation antibodies. These therapeutic antibodies seem to be more promising, with improved properties when compared to their ancestors. There are several molecules in phase II / III clinical trials and a few waiting for approvals. In addition, a large number of molecules are also in pre-clinical trials and are expected to progress through various stages of drug development over the next ten years.

The “Fc Protein and Glycoengineered Antibody Market, 2013-2023” report was commissioned to examine the various aspects of engineering an antibody to develop novel drugs and address several oncology specific diseases. With the market being fairly new, the report examines several elements of developing these next generation antibodies including technologies used for their production, site of engineering in an antibody and molecules in pipeline.

For the purposes of this report, engineered antibodies are defined as antibodies which have been modified in their Fc region. The two types of modification considered are:

  • Fc Glycoengineering (referred to as ‘Glycoengineering’ in the report)
  • Fc Protein engineering

 

Scope of the Report

The base year for the report is 2012, with estimated sales data presented for the single engineered antibody - Mogamulizumab - marketed so far.  One of the primary objectives of this report is to understand the current and future status of the engineered antibody therapeutics market. This is done by analysing:

  • Molecules in pipeline and drugs approved for marketing across various markets
  • Research programs, focused on engineered antibody therapeutics, of global pharmaceutical companies and recently established start-ups
  • Technologies to produce engineered antibodies
  • Likely adoption rate of the new drugs, some of which are expected to be used for lifecycle management of existing drugs

The report provides short-mid term and long term market forecasts for the periods 2013 - 2018 and 2018 - 2023, respectively. We have discussed, in detail, the key drivers behind the growth of this market. The research, analysis and insights presented in this report include the forecasted sales of

  • Seven marketed and pipeline glycoengineered antibodies and
  • Three pipeline Fc protein engineered antibodies

Owing to niche nature of the market, with most products in the pipeline, we provide three scenarios for our market forecast to add robustness to our model. The conservative, base and optimistic scenarios are considered for the forecasting of each of the analysed drugs. The figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  provides a general introduction on antibody based therapeutics and the historic evolution of the industry since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986. The chapter also provides details about the structure of antibodies and techniques used to engineer them. In addition to this, we also briefly discuss advantages of engineered antibodies over traditional therapeutics.

Chapter 3  provides market overview and background of the engineered antibodies market. In this chapter, we have identified the companies which are active in this market and conducted a detailed pipeline analysis of glycoengineered and Fc protein engineered antibodies.

Chapter 4  focuses on glycoengineered antibodies market, with a special emphasis on the future growth over the next ten years. The market forecast, over the next ten years, is comprised of estimated sales of one marketed drug and six others in the pipeline. We have profiled each of these drugs to provide a detailed understanding on the history of development, mechanism of action and existing / future competition.

Chapter 5  focuses on Fc protein engineered antibodies market. The market forecast, over the next ten years, is comprised of estimated sales of three drugs in the pipeline. We have profiled each of these drugs to provide a detailed understanding on the history of development, mechanism of action and existing / future competition.

Chapter 6  highlights the main technologies available for the production of engineered antibodies. We have reviewed the advantages of each technology in detail and analysed the licensing activity in recent past.

Chapter 7  includes profiles of the key companies in the engineered antibodies market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline engineered antibodies and recent developments.

Chapter 8  provides our analysis of the market under the SWOT framework. This section identifies key elements that are likely to influence future growth and / or impede the progress.

Chapter 9  summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 10  is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Table of Contents

1. EXECUTIVE SUMMARY
 
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
1.4. Key Highlights
1.4.1. Marketing Approval of Mogamulizumab / KW-0761
1.4.2. Oncology Dominates the Field of Engineered Antibodies
1.4.3. Licensing of Technology Platforms is Commonplace
1.4.4. Glycoengineered Antibodies Likely to Dominate the Market
1.4.5. Many New Opportunities Remain Unexplored
 
2. INTRODUCTION
2.1. Chapter Overview
2.2. Antibody Based Therapeutics
2.2.1. Eleven of the Approved Antibody Based Therapeutics are Non-Canonical
2.2.2. Dominance of Antibody Based Therapeutics
2.3. Monoclonal Antibody
2.3.1. How Monoclonal Antibody Therapy Works
2.3.2. Parts of a Monoclonal Antibody
2.3.3. Fc Region and Effector Functions
2.3.3.1. Types of Fc Receptors
2.3.3.2. FcγRIIIa Polymorphism
2.3.4. Engineering Fc Region
2.3.4.1. Glycoengineering
2.3.4.2. Protein Engineering
2.3.4.3. Isotype Chimerism
 
2.4. Advantages of Engineered Antibodies over Traditional Therapeutics
 
3. ENGINEERED ANTIBODIES: OVERVIEW AND BACKGROUND
 
3.1. Chapter Overview
 
3.2. A Small Market in 2013 with Only One Approved Drug
3.2.1. Mogamulizumab / KW-0761 / POTELIGEO / AMG761 (Kyowa Hakko Kirin)
 
3.3. Companies Active in the Engineered Antibodies Market
 
3.4. Technology Providers Outnumber the Drug Developers
 
3.5. Large Pharmaceutical Companies Taking Interest
 
3.6. Analysis of the Development Pipeline
3.6.1. Limited Number of Molecules in Late Stage Development
3.6.2. Cancer is the Leading Indication for Engineered Antibodies
3.6.3. Common Target Antigens for Engineered Antibodies
 
4. GLYCOENGINEERED ANTIBODIES MARKET, 2012 - 2023
 
4.1. Chapter Overview
 
4.2. Glycoengineered Antibody Market, 2012
4.2.1. Mogamulizumab / POTELIGEO was the Sole Participant in the Market in 2012
 
4.3. Glycoengineered Antibody Market Forecast, 2013-2023
4.3.1. Scope and Limitations
4.3.2. Assumptions for Market Forecast
4.3.3. Overall Glycoengineered Antibodies Market Forecast: Short-Midterm, 2013 - 2018
4.3.4. Overall Glycoengineered Antibodies Market Forecast: Long Term, 2018 - 2023
 
4.4. Mogamulizumab / POTELIGEO (Kyowa Hakko Kirin / Amgen)
4.4.1. Mechanism of Action
4.4.2. History of Development
4.4.3. Orphan Drug Designation
4.4.4. A First in Many Aspects
4.4.5. Launched With a Companion Diagnostic
4.4.6. First CCR4 Targeted Antibody to Reach the Market
4.4.7. Agreement with Amgen
4.4.8. Establishing Sales Capabilities for Mogamulizumab Outside Japan
4.4.9. Incidence and Prevalence of Targeted Indications
4.4.10. Strategies for Market Expansion
4.4.10.1. Competition from Marketed Agents
4.4.11. Mogamulizumab / POTELGEIO Sales Forecast: Short-Mid Term, 2013 - 2018
4.4.12. Mogamulizumab / POTELIGEO Sales Forecast: Long Term, 2013 - 2018
 
4.5. Obinutuzumab / GA101 (Roche / Biogen Idec)
4.5.1. Drug Specifications
4.5.2. GA101 and Rituximab: A Comparison
4.5.3. A Third Generation Anti-CD20 Therapeutic
4.5.4. A Successor to Rituxan?
4.5.4.1. CD20 Franchise
4.5.4.2. Biosimilar Competition
4.5.4.3. Factors Determining Success
4.5.5. Current Treatment Options for Targeted Indications
4.5.6. Launch and Pricing
4.5.7. Current State of Development: Indications and Timeline
4.5.8. Obinutuzumab / GA101 Sales Forecast: Short-Mid Term, 2013 - 2018
4.5.9. Obinutuzumab / GA101 Sales Forecast: Long Term, 2018 - 2023
 
4.6. Benralizumab / KHK4563 / MEDI-563 (Kyowa Hakko Kirin / MedImmune)
4.6.1. Drug Specifications
4.6.2. Product Out-licensing Deal
4.6.3. Limited Competition for Targeted Indication
4.6.4. Current Development Status
4.6.5. Benralizumab / KHK4563 / MEDI-563 Sales Forecast: Short-Mid Term, 2013 - 2018
4.6.6. Benralizumab / KHK4563 / MEDI-563 Sales Forecast: Long Term, 2018 - 2023
 
4.7. MEDI-551 (MedImmune)
4.7.1. Drug Specifications
4.7.2. Competition or Complement?
4.7.3. Current State of Development
4.7.4. MEDI-551 Sales Forecast: Long Term, 2018 - 2023
 
4.8. Ecromeximab / KW-2871 (Life Science Pharmaceuticals)
4.8.1. Drug Specifications
4.8.2. History of Development
4.8.3. Competition for Ecromeximab
4.8.4. Current State of Development
4.8.5. Ecromeximab / KW-2871 Sales Forecast: Long Term, 2018 - 2023
 
4.9. Roledumab / LFB-r593 (LFB)
4.9.1. Drug Specifications
4.9.2. Competition for Roledumab
4.9.3. Current State of Development
4.9.4. Roledumab / LFB-r593 Sales Forecast: Long Term, 2018 - 2023
 
4.10. Ublituximab / LFB-r603 / TGT-1101 (LFB / TG Therapeutics / Ildong Pharmaceuticals)
4.10.1. Drug Specifications
4.10.2. Licensing Agreement
4.10.3. Comparison with Rituximab
4.10.4. Third Generation Monoclonal Antibodies
4.10.5. Current State of Development
4.10.6. Ublituximab / LFB-r603 / TGT-1101 Sales Forecast: Short-Mid Term, 2013 - 2018
4.10.7. Ublituximab / LFB-r603 / TGT-1101 Sales Forecast: Long Term, 2018 - 2023
 
5. Fc PROTEIN ENGINEERED ANTIBODIES MARKET, 2013 - 2023
 
5.1. Chapter Overview
 
5.2. Overall Fc Protein Engineered Antibody Market Forecast, 2013-2023
5.2.1. Scope and Limitations
5.2.2. Assumptions for Market Forecast
5.2.3. Overall Fc Protein Engineered Antibodies Market Forecast: Short-Midterm, 2013-2018
5.2.4. Overall Fc Protein Engineered Antibodies Market Forecast: Long Term, 2019-2023
 
5.3. Ocaratuzumab / AME-133v (Mentrik Biotech)
5.3.1. Drug Specifications
5.3.2. History of Development
5.3.3. Current State of Development
5.3.4. A New Route of Development
5.3.5. Ocaratuzumab / AME- 133v and Rituximab: A Comparison
5.3.6. Ocaratuzumab / AME-133v Sales Forecast: Long Term, 2018 - 2023
 
5.4. Margetuximab / MGAH22 (MacroGenics)
5.4.1. Drug Specifications
5.4.2. Collaboration with Green Cross Corporation
5.4.3. HER2 Franchise
5.4.4. A Herceptin Biobetter
5.4.5. Competition for Margetuximab / MGAH22
5.4.6. Clinical Development of MGAH22
5.4.7. Margetuximab / MGAH22 Sales Forecast: Short-Mid Term, 2013 - 2018
5.4.8. Margetuximab / MGAH22 Sales Forecast: Long Term, 2018 - 2023
 
5.5. XmAb5574 / MOR208
5.5.1. Drug Specifications
5.5.2. History of Development
5.5.3. A Strategic Acquisition for MorphoSys
5.5.4. CD19 Market Landscape
5.5.5. Current State of Development
5.5.6. XmAb5574 / MOR208 Sales Forecast: Long Term, 2018 - 2023
 
5.6. Teplizumab / MGA031 (MacroGenics)
5.6.1. Drug Specifications
5.6.2. Type – 1 Diabetes
5.6.3. Mechanism of Action
5.6.4. History of Development: Highs and Lows
5.6.5. Competition for Teplizumab / MGA031
5.6.6. Current State of Development
 
6. TECHNOLOGICAL PLATFORMS FOR ENGINEERED ANTIBODIES
 
6.1. Chapter Overview
 
6.2. POTELLIGENT (BioWa, a Subsidiary of Kyowa Hakko Kirin)
6.2.1. Establishment of BioWa
6.2.2. The Technology
6.2.3. POTELLIGENT CHOK1SV: A 2-in-1 Technology
6.2.4. Pipeline of Molecules under Development
6.2.5. Companies Showing Interest in the Technology
6.2.6. Advantages of POTELLIGENT Technology
 
6.3. GlycoMab Technology (GlycArt)
6.3.1. Overview
6.3.2. Formation of Roche GlycArt
6.3.3. The Technology
6.3.3.1. Imparting Improved Binding Affinity and ADCC Activity
6.3.4. Production of GA101 Using GlycoMab Technology
6.3.5. Pipeline of Molecules under Development
6.3.6. Advantages of GlycoMab Technology
 
6.4. GlycoExpress (Glycotope)
6.4.1. Overview
6.4.2. About Glycotope
6.4.3. The Technology
6.4.4. Pipeline of Molecules under Development
6.4.5. Advantages of GlycoExpress Technology
 
6.5. GlymaxX Technology (ProBioGen)
6.5.1. Overview
6.5.2. The Technology
6.5.3. Catching the Attention of Drug Developers
6.5.4. Advantages of GlymaxX Technology
 
6.6. XmAb Fc Technology (Xencor)
6.6.1. Overview
6.6.2. The Technology
6.6.3. Pipeline of Molecules under Development
6.6.4. Pharmaceutical Companies Showing Interest in the Technology
 
6.7. Other Fc Engineering Technologies
6.7.1. EMABling Technology (LFB)
6.7.2. BryoTechnology (Greenovation Biotech)
6.7.3. MAGE 1.5 (Eureka Therapeutics)
6.7.4. Sugar Engineered Antibody (Seattle Genetics)
6.7.5. Other Technologies
 
7. PROFILE OF LEADING COMPANIES
 
7.1. Roche/Genentech
7.1.1. Acquisition of GlycArt Biotechnology to Gain Access to Glycoengineering Technology
7.1.2. Engineered Antibody Development Pipeline: Three Molecules in Clinical Development
7.1.3. Financial Performance
 
7.2. Kyowa Hakko Kirin
7.2.1. The Developer of Leading Glycoengineering Technology
7.2.2. POTELLIGENT Complemented By Complegent Platform
7.2.3. Engineered Antibody Development Pipeline: Six Molecules in Clinical Development
7.2.4. Financial Performance
 
7.3. Xencor
7.3.1. Established As Research Company with Two Technology Platforms
7.3.2. Forging Collaborations for Antibody Engineering Technology
7.3.3. Engineered Antibody Development Pipeline: Six Molecules in Clinical Development
 
7.4. Boehringer Ingelheim
7.4.1. Leading Pharmaceutical Company Opening to Oncology Space
7.4.2. Interest in Glycoengineering technology
7.4.3. Exploring the Fc Engineering Technology
7.4.4. Engineered Antibody Development Pipeline: Three Molecules in Clinical Development
7.4.5. Financial Performance
 
7.5. Glycotope
7.5.1. A Leading Biotechnology Company in Germany
7.5.2. Developer of GlycoExpress
7.5.3. Engineered Antibody Development Pipeline: Three Molecules in Clinical Development
 
7.6. MacroGenics
7.6.1. Company Overview
7.6.2. Supporting Next Generation Antibody Therapeutics
7.6.3. Engineered Antibody Development Pipeline: Three Molecules in Clinical Development
 
8. SWOT ANALYSIS
 
8.1. Strengths
 
8.2. Weaknesses
 
8.3. Opportunities
 
8.4. Threats
 
9. CONCLUSIONS
 
9.1. The Pipeline is Rich
 
9.2. Key Driving Factors
 
9.3. Market is in its Infancy, with a Huge Potential for Growth
 
9.4. An Attractive Market for Large Pharmaceutical Companies
 
9.5. Concluding Remarks
 
10. APPENDIX 1: TABLES
 
11. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

List of Figures

Figure 2.1 Number of Approved non-Canonical Antibody Based Therapeutics
Figure 2.2 Sales (USD MM) of Top 10 Drugs, 2012
Figure 3.1 Companies Active in the Glycoengineered Antibodies Market: Number of Molecules in Development
Figure 3.2 Companies Active in the Fc Protein Engineered Antibodies Market: Number of Molecules in Development
Figure 3.3 Engineered Antibodies in Clinical Development, Share (%) by Phase of Development
Figure 3.4 Engineered Antibodies in Clinical Development, Share (%) by Target Antigens
Figure 4.1 Overall Glycoengineered Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Base Scenario)
Figure 4.2 Overall Glycoengineered Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.3 Mogamulizumab / POTELIGEO Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Figure 4.4 Mogamulizumab / POTELIGEO Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.5 Obinutuzumab / GA101: Development Plans
Figure 4.6 Rituximab Sales by Indication (%), 2012
Figure 4.7 Obinutuzumab / GA101 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Figure 4.8 Obinutuzumab / GA101 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.9 Benralizumab / KHK4563 / MEDI-563 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Figure 4.10 Benralizumab / KHK4563 / MEDI-563 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.11 MEDI-551 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.12 Ecromeximab / KW-2871 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.13 Roledumab / LFB-r593 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 4.14 Ublituximab / LFB-r603 / TGT-1101 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Figure 4.15 Ublituximab / LFB-r603 / TGT-1101 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 5.1 Overall Fc Protein Engineered Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Base Scenario)
Figure 5.2 Overall Fc Protein Engineered Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 5.3 Ocaratuzumab / AME-133v Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 5.4 HER2 Franchise Sales Performance – Roche Group (USD MM), 2012 and 1Q 2013
Figure 5.5 Margetuximab / MGAH22 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Figure 5.6 Margetuximab / MGAH22 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 5.7 XmAb5574 / MOR208 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Figure 7.1 Roche Group Sales Performance (USD BN), 2011 and 2012
Figure 7.2 Kyowa Hakko Kirin Sales Performance (JPY BN), 2011 and 2012
Figure 7.3 Boehringer Ingelheim Sales Performance (EUR MM), 2011 and 2012
Figure 9.1 Glycoengineered Antibodies Market Forecast (USD MM): 2016, 2019, 2023
Figure 9.2 Fc Protein Engineered Antibodies Market Forecast (USD MM): 2016, 2019, 2023

List of Tables

Table 2.1 Approved Antibody Based Therapeutics
Table 3.1 Companies Providing Glycoengineering Technology
Table 3.2 Companies Providing Fc Protein Engineering Technology
Table 3.3 Glycoengineered Antibodies in Development, 2013
Table 3.4 Fc Protein Engineered Antibodies in Development, 2013
Table 4.1 Current Development Phase and Expected Launch Year of Glycoengineered Antibodies in Clinical Development (Phase II and Higher)
Table 4.2 Orphan Drug Designation for Mogamulizumab
Table 4.3 Mogamulizumab / POTELIGEO: Ongoing Clinical Trials
Table 4.4 FDA Approved Drugs for CTCL, 2012
Table 4.5 Anti-CD20 Antibody Based Therapeutics Landscape
Table 4.6 Rituximab Biosimilars Under Development, 2013
Table 4.7 Obinutuzumab / GA101: Ongoing Clinical Trials
Table 4.8 Antibody Therapeutics Under Development for Eosinophilic Asthma
Table 4.9 Benralizumab / MEDI-563 / KHK4563: Ongoing Clinical Trials
Table 4.10 MEDI-551: Ongoing Clinical Trials
Table 4.11 Drugs Available / Under Development for Metastatic Melanoma
Table 4.12 Ublituximab / LFB-r603 / TGT-1101: Ongoing clinical trials
Table 5.1 Current Development Phase and Expected Launch Year of Fc Protein Engineered Antibodies in Clinical Development (Phase II and Higher)
Table 5.2 Ocaratuzumab / AME-133v: Active and Planned Clinical Trials
Table 5.3 List of Trastuzumab Biosimilars Under Development, 2013
Table 5.4 Anti-CD19 Antibody Based Therapeutics Landscape
Table 5.5 XmAb5574 / MOR208: Active Clinical Trials
Table 5.6 Type-1 Diabetes: Drugs Under Development
Table 5.7 Teplizumab / MGA031: Ongoing Clinical Trials
Table 6.1 POTELIGENT: Molecules Under Clinical Trials
Table 6.2 Technology Licensing Agreements for POTELLIGENT
Table 6.3 Comparison of Kd for Rituximab and GA101
Table 6.4 GlycoMab: Molecules Under Clinical Trials
Table 6.5 GlycoExpress: Molecules Under Clinical Trials
Table 6.6 XmAb: Molecules Under Clinical Trials
Table 6.7 Xencor Licensing Agreements, 2007-2013
Table 6.8 EMABling Technology: Drugs Under Development
Table 7.1 Roche: Engineered Antibodies Under Development
Table 7.2 Kyowa Hakko Kirin: Engineered Antibodies Under Development
Table 7.3 Xencor: Engineered Antibodies Under Development
Table 7.4 Boehringer Ingelheim: Engineered Antibodies Under Development
Table 7.5 Glycotope: Engineered Antibodies Under Development
Table 7.6 MacroGenics: Engineered Antibodies Under Development
Table 8.1 SWOT Analysis of Engineered Antibodies Market
Table 10.1Approved non-Canonical Antibody Based Therapeutics
Table 10.2 Sales (USD) of top 10 drugs, 2012
Table 10.3 Engineered Antibodies in Clinical Development, Share (%) by Phase of Development
Table 10.4 Engineered Antibodies in Clinical Development, Share (%) by Target Antigens
Table 10.5 Overall Glycoengineered Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Base Scenario)
Table 10.6 Overall Glycoengineered Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Conservative Scenario)
Table 10.7 Overall Glycoengineered Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Optimistic Scenario)
Table 10.8 Overall Glycoengineered Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.9 Overall Glycoengineered Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.10 Overall Glycoengineered Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Aggressive Scenario)
Table 10.11 Mogamulizumab / POTELIGEO Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Table 10.12 Mogamulizumab / POTELIGEO Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Conservative Scenario)
Table 10.13 Mogamulizumab / POTELIGEO Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Aggressive Scenario)
Table 10.14 Mogamulizumab / POTELIGEO Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.15 Mogamulizumab / POTELIGEO Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.16 Mogamulizumab / POTELIGEO Market (USD MM), Long Term Forecast: 2018 - 2023 (Aggressive Scenario)
Table 10.17 Rituximab Sales by Indication (%), 2012
Table 10.18 Obinutuzumab / GA101 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Table 10.19 Obinutuzumab / GA101 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Conservative Scenario)
Table 10.20 Obinutuzumab / GA101 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Aggressive Scenario)
Table 10.21 Obinutuzumab / GA101 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.22 Obinutuzumab / GA101 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.23 Obinutuzumab / GA101 Market (USD MM), Long Term Forecast: 2018 - 2023 (Aggressive Scenario)
Table 10.24 Benralizumab / KHK4563 / MEDI-563 Market (USD MM), Short-Mid Term Forecast:   2013 - 2018 (Base Scenario)
Table 10.25 Benralizumab / KHK4563 / MEDI-563 Market (USD MM), Short-Mid Term Forecast:   2013 - 2018 (Conservative Scenario)
Table 10.26 Benralizumab / KHK4563 / MEDI-563 Market (USD MM), Short-Mid Term Forecast:   2013 - 2018 (Aggressive Scenario)
Table 10.27 Benralizumab / KHK4563 / MEDI-563 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.28 Benralizumab / KHK4563 / MEDI-563 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.29 Benralizumab / KHK4563 / MEDI-563 Market (USD MM), Long Term Forecast: 2018 - 2023 (Aggressive Scenario)
Table 10.30 MEDI-551 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.31 MEDI-551 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.32 MEDI-551 Market (USD MM), Long Term Forecast: 2018 - 2023 (Aggressive Scenario)
Table 10.33 Ecromeximab / KW-2871 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.34 Ecromeximab / KW-2871 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.35 Ecromeximab / KW-2871 Market (USD MM), Long Term Forecast: 2018 - 2023 (Aggressive Scenario)
Table 10.36 Roledumab / LFB-r593 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.37 Roledumab / LFB-r593 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.38 Roledumab / LFB-r593 Market (USD MM), Long Term Forecast: 2018 - 2023 (Aggressive Scenario)
Table 10.39 Ublituximab / LFB-r603 / TGT-1101 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Table 10.40 Ublituximab / LFB-r603 / TGT-1101 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Conservative Scenario)
Table 10.41 Ublituximab / LFB-r603 / TGT-1101 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Aggressive Scenario)
Table 10.42 Ublituximab / LFB-r603 / TGT-1101 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.43 Ublituximab / LFB-r603 / TGT-1101 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.44 Ublituximab / LFB-r603 / TGT-1101 Market (USD MM), Long Term Forecast: 2018 - 2023 (Aggressive Scenario)
Table 10.45 Overall Fc Protein Engineered Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Base Scenario)
Table 10.46 Overall Fc Protein Engineered Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Conservative Scenario)
Table 10.47 Overall Fc Protein Engineered Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Aggressive Scenario)
Table 10.48 Overall Fc Protein Engineered Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.49 Overall Fc Protein Engineered Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.50 Overall Fc Protein Engineered Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Aggressive Scenario)
Table 10.51 Ocaratuzumab / AME-133v Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.52 Ocaratuzumab / AME-133v Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.53 Ocaratuzumab / AME-133v Market (USD MM), Long Term Forecast: 2018 - 2023 (Aggressive Scenario)
Table 10.54 HER2 Franchise Sales Performance – Roche Group (USD MM), 2012 and 1Q 2013
Table 10.55 Margetuximab / MGAH22 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)
Table 10.56 Margetuximab / MGAH22 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Conservative Scenario)
Table 10.57 Margetuximab / MGAH22 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Aggressive Scenario)
Table 10.58 Margetuximab / MGAH22 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.59 Margetuximab / MGAH22 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.60 Margetuximab / MGAH22 Market (USD MM), Long Term Forecast: 2018 - 2023 (Aggressive Scenario)
Table 10.61 XmAb5574 / MOR208 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)
Table 10.62 XmAb5574 / MOR208 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)
Table 10.63 XmAb5574 / MOR208 Market (USD MM), Long Term Forecast: 2018 - 2023 (Aggressive Scenario)

Listed Companies

The following companies have been mentioned in this report

  1. ABN AMRO Capital
  2. Absolute Antibody
  3. Accurus Biosciences
  4. Affitech A/S
  5. Allos Therapeutics
  6. Amgen
  7. Andromeda Biotech
  8. Applied Molecular Evolution (AME)
  9. arGEN-X
  10. Astra Zeneca
  11. AVID Bioservices
  12. biOasis Technologies
  13. Bioceros
  14. Biocon
  15. Biogen Idec
  16. BioMedinvest
  17. BioWa
  18. BioXcellence
  19. BioXpress Therapeutics
  20. Boehringer Ingelheim
  21. Bristol Myers Squibb
  22. Celltrion
  23. Centocor Ortho Biotech
  24. Cephalon
  25. ChemoCentryx
  26. Chugai Pharmaceuticals
  27. CSL
  28. Deutsche Venture Capital
  29. Diamyd Medical
  30. Dong-A Pharmaceutical
  31. Eli Lilly
  32. Eureka Therapeutics
  33. Five Prime Therapeutics
  34. Genentech
  35. Gilde Investment Management
  36. Global Life Science Ventures
  37. Glycart
  38. Glycode
  39. Glycotope
  40. Green Cross Corporation
  41. Greenovation
  42. GSK
  43. Halozyme Therapeutics
  44. Hanwha Chemical
  45. Human Genome Sciences
  46. Ildong Pharmaceuticals
  47. ImmunGene
  48. Inhibrx
  49. InvivoGen
  50. ISU Abxis
  51. KaloBios
  52. Kyowa Hakko Kirin
  53. Laboratoire français du Fractionnement et des Biotechnologies (LFB)
  54. Life Science Pharmaceuticals
  55. Lonza
  56. MacroGenics
  57. MedImmune
  58. Meiji Seika Pharma
  59. Mentrik Biotech
  60. Merck-GlycoFi
  61. Micromet
  62. MilleGen
  63. Minapharm Pharmaceuticals
  64. Morphosys
  65. Mylan
  66. Nippon Kayaku
  67. Nippon Shinyaku
  68. NKT Therapeutics
  69. Novartis
  70. Novartis Venture Fund
  71. Ortho-McNeil Janssen Pharmaceutical
  72. PDL Biopharma
  73. Pfizer
  74. Pikamab
  75. Pinnacle Oncology Hematology
  76. PlantForm Corporation
  77. ProStrakan
  78. Quester Capital Management
  79. Regeneron Pharmaceuticals
  80. rEVO Biologic
  81. Roche
  82. Sandoz
  83. Sanofi
  84. Schnell Biopharma
  85. Seattle Genetics
  86. Servier
  87. Shanghai CP Guojian
  88. SiaMedExpress
  89. Sorrento Therapeutics
  90. Synthon-Biolex
  91. Taiho Pharmaceutical
  92. Teva Pharmaceuticals
  93. TG Therapeutics
  94. Trubion
  95. Vivalis
  96. Watson Pharmaceuticals
  97. WuXi AppTec
  98. Xencor
  99. Zymeworks

The following organisations have been mentioned in this report:

  1. American Society of Clinical Oncology (ASCO)
  2. American Society of Hematology
  3. Cutaneous Lymphoma Foundation
  4. Dana-Farber Cancer Institute
  5. European Medicines Agency (EMA)
  6. US Food and Drug Administration (US FDA)
  7. IBC Generium
  8. Ludwig Institute for Cancer Research (LICR)
  9. National Institute for Health and Clinical Excellence (NICE)
  10. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  11. Swiss Federal Institute of Technology
  12. United States Patent and Trademark Office (USPTO)
  13. University of Chicago
  14. University of Pittsburgh Cancer Institute (UPCI)

PRICING DETAILS

USD 1,699

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.